Sharma P, Jaffe P E, Bhattacharyya A, Sampliner R E
Departments of Medicine and Pathology, Section of Gastroenterology, University of Arizona Health Sciences Center and Tucson VA Medical Center, Tucson, Arizona, USA.
Gastrointest Endosc. 1999 Apr;49(4 Pt 1):442-6. doi: 10.1016/s0016-5107(99)70040-4.
Endoscopic ablation of Barrett's esophagus, including associated dysplasia and adenocarcinoma, can be achieved by various techniques, but few long-term results are available. The aim of our study was ablation of intramucosal adenocarcinoma with a combination of Nd:YAG laser plus multipolar electrocoagulation.
Patients with documented Barrett's esophagus and adenocarcinoma who either had refused surgery or were poor candidates for surgery because of high risk were offered endoscopic therapy. Patients underwent therapy with Nd:YAG laser and multipolar electrocoagulation. They were treated with omeprazole (20 mg twice daily) as maintenance therapy.
Six patients were enrolled in the study over a 7-year period. All were men with a mean age of 78.2 years. The mean length of Barrett's esophagus was 6.0 cm (range, 3 to 10 cm). Seventeen Nd:YAG laser (mean, 2.8/patient) and 20 multipolar electrocoagulation (mean, 3.3/patient) sessions were used during the study period. All patients had a complete initial response to therapy. One patient on chronic immunosuppressive medications had recurrence of the tumor after an initial complete response (36-month follow-up). Two patients have no evidence of Barrett's esophagus, and 3 patients have residual intestinal metaplasia on biopsy of an irregular appearing "neo" Z-line. Mean follow-up in this group is 3.4 years (range, 9 to 86 months).
Laser photocoagulation and multipolar electrocoagulation can be successfully and safely used to ablate intramucosal adenocarcinoma in the setting of Barrett's esophagus. Patients remain functional with normal swallowing.
巴雷特食管(包括相关的发育异常和腺癌)的内镜下消融可通过多种技术实现,但长期结果较少。我们研究的目的是采用Nd:YAG激光联合多极电凝术消融黏膜内腺癌。
对于已确诊为巴雷特食管和腺癌且拒绝手术或因高风险而不适合手术的患者,提供内镜治疗。患者接受Nd:YAG激光和多极电凝术治疗。给予奥美拉唑(每日两次,每次20毫克)作为维持治疗。
在7年期间,6例患者纳入本研究。均为男性,平均年龄78.2岁。巴雷特食管的平均长度为6.0厘米(范围3至10厘米)。在研究期间,共进行了17次Nd:YAG激光治疗(平均每位患者2.8次)和20次多极电凝治疗(平均每位患者3.3次)。所有患者对治疗均有完全的初始反应。1例长期接受免疫抑制治疗的患者在初始完全缓解后(36个月随访)肿瘤复发。2例患者活检显示无巴雷特食管证据,3例患者在不规则出现的“新”Z线活检时有残留肠化生。该组患者的平均随访时间为3.4年(范围9至86个月)。
激光光凝术和多极电凝术可成功、安全地用于消融巴雷特食管背景下的黏膜内腺癌。患者吞咽功能正常,生活不受影响。